Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049577 | 0.83 | EPHX2 (1.00) | POLBEPHX2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3454750 | 0.83 | EPHX2 (1.00) | POLBEPHX2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6543337 | 0.83 | POLB (0.58) | POLBEPHX2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL11627185 | 0.81 | EPHX2 (0.61) | POLBEPHX2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5051860 | 0.80 | EPHX2 (0.68) | POLBEPHX2SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1800332 | 0.80 | EPHX2 (0.74) | POLBEPHX2SIGMAR1KMT2AMEN1 | |
| SCHEMBL6543070 | 0.80 | POLB (0.55) | POLBEPHX2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL23417659 | 0.80 | EPHX2 (0.68) | EPHX2SIGMAR1KMT2AMEN1NPC1 | |
| SCHEMBL13929336 | 0.79 | SIGMAR1 (0.74) | SIGMAR1 | |
| SCHEMBL11629518 | 0.79 | EPHX2 (0.70) | POLBEPHX2SIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | POLB 1063/4885EPHX2 908/4885CYP1A2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.